Back to Search
OLAF STUVE, MD
MD
Neurology Physician
NPI: 1760442420Individual
Specialties, Licenses & Credentials
Neurology PhysicianPrimary
Psychiatry & Neurology — Neurology
Code: 2084N0400X
M0936(TX)
Clinical Trials (2)
2
Linked Trials
0
Recruiting
1
With Results
Research & Publications (20)
The sequential natalizumab - alemtuzumab therapy in patients with relapsing forms of multiple sclerosis (SUPPRESS) trial - Part I: Rationale and objectives.
PMID 36062026·J Cent Nerv Syst Dis·2022
8-other
Diagnosis of multiple sclerosis: revisions of the McDonald criteria 2017 - continuity and change.
PMID 30985371·Curr Opin Neurol·2019
6-review
Reduced brain atrophy rates are associated with lower risk of disability progression in patients with relapsing multiple sclerosis treated with cladribine tablets.
PMID 28140753·Mult Scler·2018
2-rct
Long-term effects of cladribine tablets on MRI activity outcomes in patients with relapsing-remitting multiple sclerosis: the CLARITY Extension study.
PMID 29399054·Ther Adv Neurol Disord·2018
8-other
Safety and efficacy of cladribine tablets in patients with relapsing-remitting multiple sclerosis: Results from the randomized extension trial of the CLARITY study.
PMID 28870107·Mult Scler·2018
2-rct
Natalizumab: Perspectives from the Bench to Bedside.
PMID 29500304·Cold Spring Harb Perspect Med·2018
6-review
Natalizumab for Multiple Sclerosis: A Case in Point for the Impact of Translational Neuroimmunology.
PMID 28167648·J Immunol·2017
6-review
Defining the clinical course of multiple sclerosis: the 2013 revisions.
PMID 24871874·Neurology·2014
8-other
Effect of oral cladribine on time to conversion to clinically definite multiple sclerosis in patients with a first demyelinating event (ORACLE MS): a phase 3 randomised trial.
PMID 24502830·Lancet Neurol·2014
3-trial
Systematic literature review and validity evaluation of the Expanded Disability Status Scale (EDSS) and the Multiple Sclerosis Functional Composite (MSFC) in patients with multiple sclerosis.
PMID 24666846·BMC Neurol·2014
1-meta
Does risk stratification decrease the risk of natalizumab-associated PML? Where is the evidence?
PMID 24812045·Mult Scler·2014
8-other
Clinical relevance of differential lymphocyte recovery after alemtuzumab therapy for multiple sclerosis.
PMID 23243077·Neurology·2013
3-trial
MRI outcomes with cladribine tablets for multiple sclerosis in the CLARITY study.
PMID 23263473·J Neurol·2013
3-trial
Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial.
PMID 23122650·Lancet·2012
3-trial
Long term lymphocyte reconstitution after alemtuzumab treatment of multiple sclerosis.
PMID 22056965·J Neurol Neurosurg Psychiatry·2012
8-other
Alemtuzumab more effective than interferon β-1a at 5-year follow-up of CAMMS223 clinical trial.
PMID 22442431·Neurology·2012
4-observational
Risk of natalizumab-associated progressive multifocal leukoencephalopathy.
PMID 22591293·N Engl J Med·2012
8-other
Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial.
PMID 23122652·Lancet·2012
3-trial
Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis.
PMID 21543733·Neurology·2011
8-other
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 5323 HARRY HINES BLVD
DALLAS, TX 75390 - Phone
- (214) 645-0624
Quick Facts
- NPI
- 1760442420
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 1
- Clinical Trials
- 2
- Publications
- 20
Are you this provider?
Claim Your Profile